{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T18:28:23Z","timestamp":1758479303418},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,12,24]],"date-time":"2009-12-24T00:00:00Z","timestamp":1261612800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1007\/s00228-009-0767-8","type":"journal-article","created":{"date-parts":[[2009,12,23]],"date-time":"2009-12-23T07:34:44Z","timestamp":1261553684000},"page":"375-381","source":"Crossref","is-referenced-by-count":8,"title":["Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting"],"prefix":"10.1007","volume":"66","author":[{"given":"Annette","family":"Haberl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Moesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Nisius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Stephan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Bickel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Khaykin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kurowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"Brodt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils","family":"von Hentig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,12,24]]},"reference":[{"key":"767_CR1","unstructured":"Bristol Myers Squibb Company (2007) Reyataz product information. NDA 21-567\/S-012. Bristol Meyers Squib, Princeton, NJ"},{"key":"767_CR2","unstructured":"CBER (1999) Guidance for the industry. In vivo drug metabolism\/drug interactions studies. Study design, data analysis and recommendations for dosing and labeling. Center for Biologics Evaluation and Research (CBER), Rockville"},{"key":"767_CR3","unstructured":"Burger DM, Muller RJ, van der Leur MR, la Porte CJL (2002) Lopinavir plasma levels are significantly higher in female than in male HIV-1 infected patients. In: Program and abstracts of the 3rd Int Workshop Clinical Pharmacology of HIV Therapy. Washington D.C."},{"key":"767_CR4","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jpba.2007.02.014","volume":"44","author":"R DiFrancesco","year":"2007","unstructured":"DiFrancesco R, Fischl MA, Donnelly J, Zingman BS, McCance-Katz EF, Moody DE, Reichman RC, Gripshover B, Morse GD (2007) Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users. J Pharm Biomed Anal 44:188\u2013195","journal-title":"J Pharm Biomed Anal"},{"key":"767_CR5","doi-asserted-by":"crossref","unstructured":"Esser S, Staszewski S, Haberl A, Mulcahy F, G\u00f6lz J, Lazzarin A, Teofilo E, Vera J, K\u00f6rber A, Ranneberg B, Gallo L (2008) 3OD\u2014Once-daily (OD) TDF-containing HAART in HIV-1-infected former IVDU-patients receiving opiate substitution: efficacy, tolerability and adherence. In: 9th Int Congress Drug Therapy in HIV Infection. Glasgow","DOI":"10.1186\/1758-2652-11-S1-P76"},{"key":"767_CR6","doi-asserted-by":"crossref","unstructured":"Esser S, Staszewski S, Haberl A, Mulcahy F, G\u00f6lz J, Lazzarin A, Teofilo E, Vera J, K\u00f6rber A, Ranneberg B, Gallo L (2008) An open-label multicenter study to assess efficacy, tolerability and adherence of a once-daily (OD) TDF-Containing HAART in HIV-1-Infected Former IVDU-Patients receiving opiate substitution\u2014final 48\u00a0weeks analysis of 3OD. In: 17th International AIDS Conference. Mexico City, Mexico","DOI":"10.1186\/1758-2652-11-S1-P76"},{"key":"767_CR7","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1097\/01.aids.0000183628.20041.f2","volume":"19","author":"G Friedland","year":"2005","unstructured":"Friedland G, Andrews L, Schreibman T, Agarwala S, Daley L, Child M, Shi J, Wang Y, O'Mara E (2005) Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. Aids 19:1635\u20131641","journal-title":"Aids"},{"key":"767_CR8","unstructured":"Gatti G, De Pascalis CR, De Luca A et al (2002) Predictors of amprenavir parameters of drug exposure in heavily pretreated HIV positive patients (abstract). In: Proc 6th Int Congress in Drug Therapy in HIV Infection. Glasgow, p 165"},{"key":"767_CR9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/bdd.482","volume":"27","author":"PH Hsyu","year":"2006","unstructured":"Hsyu PH, Lillibridge J, Daniels E, Kerr BM (2006) Pharmacokinetic interaction of nelfinavir and methadone in intravenous drug users. Biopharm Drug Dispos 27:61\u201368","journal-title":"Biopharm Drug Dispos"},{"key":"767_CR10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1365-2524.2005.00542.x","volume":"13","author":"V Johnson","year":"2005","unstructured":"Johnson V, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes D, Pillay D, Schapiro J, Telenti A, Richman D (2005) Update of the drug resistance mutations in HIV-1: 2005. Topics HIV Med 13:125\u2013131","journal-title":"Topics HIV Med"},{"key":"767_CR11","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1046\/j.1468-1293.2003.00143.x","volume":"4","author":"M Kurowski","year":"2003","unstructured":"Kurowski M, Sternfeld T, Sawyer A, Hill A, Mocklinghoff C (2003) Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers. HIV Med 4:94\u2013100","journal-title":"HIV Med"},{"key":"767_CR12","doi-asserted-by":"crossref","unstructured":"McCance-Katz EF, Moody DE, Morse GD, Ma Q, Difrancesco R, Friedland G, Pade P, Rainey PM (2007) Interaction between buprenorphine and atazanavir or atazanavir\/ritonavir. Drug Alcohol Depend 91:269\u2013278","DOI":"10.1016\/j.drugalcdep.2007.06.007"},{"key":"767_CR13","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1592\/phco.24.6.592.34744","volume":"24","author":"MP Pai","year":"2004","unstructured":"Pai MP, Schriever CA, Diaz-Linares M, Novak RM, Rodvold KA (2004) Sex-related differences in the pharmacokinetics of once-daily saquinavir soft-gelatin capsules boosted with low-dose ritonavir in patients infected with human immunodeficiency virus type 1. Pharmacotherapy 24:592\u2013599","journal-title":"Pharmacotherapy"},{"key":"767_CR14","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00002030-200402200-00017","volume":"18","author":"C Stephan","year":"2004","unstructured":"Stephan C, Hentig N, Kourbeti I, Dauer B, Mosch M, Lutz T, Klauke S, Harder S, Kurowski M, Staszewski S (2004) Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir\/ritonavir. Aids 18:503\u2013508","journal-title":"Aids"},{"key":"767_CR15","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/QAI.0b013e318061b5fd","volume":"45","author":"HK Tossonian","year":"2007","unstructured":"Tossonian HK, Raffa JD, Grebely J, Trotter B, Viljoen M, Mead A, Khara M, McLean M, Duncan F, Fraser C, DeVlaming S, Conway B (2007) Methadone dosing strategies in HIV-infected injection drug users enrolled in a directly observed therapy program. J Acquir Immune Defic Syndr 45:324\u2013327","journal-title":"J Acquir Immune Defic Syndr"},{"key":"767_CR16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1517\/17425255.2.2.273","volume":"2","author":"O Umeh","year":"2006","unstructured":"Umeh O, Currier J (2006) Sex differences in the pharmacokinetics and toxicity of antiretroviral therapy. Expert Opin Drug Metab Toxicol 2:273\u2013283","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"767_CR17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1358\/dot.2008.44.2.1137107","volume":"44","author":"N Hentig von","year":"2008","unstructured":"von Hentig N (2008) Atazanavir\/ritonavir: a review of its use in HIV therapy. Drugs Today (Barc) 44:103\u2013132","journal-title":"Drugs Today (Barc)"},{"key":"767_CR18","doi-asserted-by":"crossref","unstructured":"von Hentig N, Babacan E, Stephan C, Lennemann T, Knecht G, Carlebach A, Harder S, Staszewski S, Haberl A (2008) Pharmacokinetics of atazanavir\/ritonavir in HIV-1 infected adult outpatients is not affected by gender-related cofactors. J Antimicrob Chemother 62:579\u2013582","DOI":"10.1093\/jac\/dkn204"},{"key":"767_CR19","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00228-007-0344-y","volume":"63","author":"N Hentig von","year":"2007","unstructured":"von Hentig N, Dauer B, Haberl A, Klauke S, Lutz T, Staszewski S, Harder S (2007) Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults. Eur J Clin Pharmacol 63:935\u2013940","journal-title":"Eur J Clin Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-009-0767-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-009-0767-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-009-0767-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T21:23:55Z","timestamp":1634592235000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-009-0767-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,24]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["767"],"URL":"https:\/\/doi.org\/10.1007\/s00228-009-0767-8","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,24]]}}}